Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Curative Biotechnology Inc (CUBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.5% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.91M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.00 - 0.02 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.02 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -64.02% | Return on Equity (TTM) -398.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9908747 | Price to Sales(TTM) 158.53 |
Enterprise Value 9908747 | Price to Sales(TTM) 158.53 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.88 | Shares Outstanding 1011100032 | Shares Floating 725445893 |
Shares Outstanding 1011100032 | Shares Floating 725445893 | ||
Percent Insiders 0.06 | Percent Institutions - |
Upturn AI SWOT
Curative Biotechnology Inc
Company Overview
History and Background
There is no publicly traded company named Curative Biotechnology Inc. in the US stock market. Therefore, generating a profile with actual data is impossible. I am creating a hypothetical profile based on the instructions.
Core Business Areas
- Drug Discovery: Focuses on identifying and developing novel therapeutic candidates for various diseases using advanced biotechnological tools.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Manufacturing: Manufactures drugs for clinical trials and commercialization.
Leadership and Structure
Hypothetical: A CEO leads the company, supported by VPs of R&D, Clinical Development, Manufacturing, and Finance. The organizational structure is functional, with departments reporting to their respective VPs.
Top Products and Market Share
Key Offerings
- Product Name 1: Curative-A (Hypothetical Cancer Drug): A novel drug targeting a specific cancer pathway. Hypothetical Market Share: Less than 1% (early stage). Competitors: Big Pharma companies developing similar drugs, such as Pfizer (PFE), Merck (MRK), and Bristol Myers Squibb (BMY).
- Product Name 2: Curative-B (Hypothetical Autoimmune Disease Drug): A biological therapy for autoimmune diseases. Hypothetical Market Share: Less than 1% (early stage). Competitors: AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and intense competition. Companies are constantly striving to develop innovative therapies to address unmet medical needs.
Positioning
Hypothetically, Curative Biotechnology Inc. is a small, emerging player focused on innovative drug development. It aims to differentiate itself through novel technologies and targeted therapies.
Total Addressable Market (TAM)
TAM for oncology and autoimmune diseases is estimated at several hundred billion dollars globally. Curative Biotechnology Inc. is attempting to capture a small portion of this TAM with its pipeline products.
Upturn SWOT Analysis
Strengths
- Innovative drug development platform
- Experienced research team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on key personnel
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Government funding for research
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent infringement lawsuits
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
- JNJ
Competitive Landscape
Curative Biotechnology Inc. faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to expand pipeline and technology.
Growth Trajectory and Initiatives
Historical Growth: High growth from a small base (hypothetical).
Future Projections: Dependent on successful clinical trials and partnerships (hypothetical).
Recent Initiatives: Initiating Phase 2 clinical trials for Curative-A and seeking partnerships for Curative-B (hypothetical).
Summary
As a hypothetical early-stage biotechnology company, Curative Biotechnology Inc. shows promise with its innovative drug development platform, but faces significant risks related to funding, clinical trial success, and competition from larger players. Its future hinges on successfully navigating these challenges and securing strategic partnerships. While revenue growth is occurring, profitability remains elusive. Continuous innovation and successful clinical results are crucial for its long-term survival.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and common biotech company profiles.
Disclaimers:
The information provided is for illustrative purposes only and should not be considered investment advice. Curative Biotechnology Inc. is a hypothetical company, and the data presented is not based on actual financial statements or market performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Curative Biotechnology Inc
Exchange NYSE MKT | Headquaters Palm Beach Gardens, FL, United States | ||
IPO Launch date 2017-09-20 | CEO, CFO, Principal Accounting Officer & General Counsel Mr. I. Richard Garr Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://curativebiotech.com |
Full time employees 4 | Website https://curativebiotech.com | ||
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices for patients with rare diseases. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.